3-(2,4-difluorophenyl)acrylic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-(2,4-difluorophenyl)acrylic acid
• 英文别名: 2,4-difluorocinnamic acid；3-(2,4-difluorophenyl)prop-2-enoic acid
• 化学式: C₉H₆F₂O₂
• mdl: MFCD00010317
• 分子量: 184.142
• InChiKey: PQDXPFJQTKGTFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2,4-difluorophenyl)acrylic acid 在 platinum(IV) oxide sodium hydroxide 、 三氯化铝 、 草酰氯 、 氢气 、 碘 、 N,N-二甲基甲酰胺 、 三氟乙酸 、 锌 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 110.58h， 生成 (E)-2-(4,6-difluoro-1-indanylidene)acetamide
  参考文献：
  名称：

  茚满亚胺。1.设计和合成（E）-2-（4,6-二氟-1-茚二亚基）乙酰胺，这是一种具有消炎和镇痛作用的强效中枢肌肉松弛剂。

  摘要：

  衍生自肉桂酰胺1，（E）-N-环丙基-3-（3-氟苯基）丙-2-烯酰胺和β-甲基肉桂酰胺2，（E）-N-环丙基-3-（3）的刚性环状类似物的设计-氟苯基）丁-2-烯酰胺已导致发现有效的中枢性肌肉松弛剂（E）-2-（4,6-二氟-1-茚二亚基）乙酰胺17。化合物17还具有有效的抗炎和抗炎作用。镇痛作用。本文描述了17和67类似物的合成及其肌肉松弛，抗炎和止痛结构-活性的关系。化合物17已进入I期临床试验。

  DOI：

  10.1021/jm020067s
• 作为产物：
  描述：

  丙二酸 、 2,4-二氟苯甲醛 在 哌啶 、 吡啶 作用下， 反应 2.0h， 以9.5 g的产率得到3-(2,4-difluorophenyl)acrylic acid
  参考文献：
  名称：

  4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVE OR SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  本发明提供了一种4,5-二氢-1H-吡唑烷衍生物或其药用可接受盐，以及其制备方法和包含该衍生物的药物组合物。4,5-二氢-1H-吡唑烷衍生物或其药用可接受盐有效增加LXR转录活性，因此可以有效地用于预防或治疗胆固醇代谢功能障碍，如胆固醇结石、高脂血症或冠状动脉粥样硬化。

  公开号：

  US20150291563A1

文献信息

• ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：Moorman Allan R.

  公开号：US20080242672A1

  公开（公告）日：2008-10-02

  The present invention provides compounds of the formula wherein R 1 and R 2 have meaning as defined herein in the specification. The compounds of formula (I) are adenosine A 2A receptor antagonists and, thus, may be employed for the treatment of conditions and diseases mediated by the adenosine A 2A receptor activity. Such conditions include, but are not limited to, diseases of the central nervous system such as depression, cognitive function diseases and neurodegenerative diseases such as Parkinson's disease, senile dementia as in Alzheimer's disease or psychoses and stroke. The compounds of the present invention may also be employed for the treatment of attention related disorders such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD), extra pyramidal syndrome, e.g., dystonia, akathisia, pseudoparkinsonism and tardive dyskinesia, and disorders of abnormal movement such as restless leg syndrome (RLS) and periodic limb movement in sleep (PLMS); cirrhosis, and fibrosis and fatty liver; dermal fibrosis in diseases such as scleroderma; and the mitigation of addictive behavior. In particular, the compounds of the present invention may be employed to improve motor-impairment due to neurodegenerative diseases such as Parkinson's disease.

  本发明提供了以下式的化合物 其中R 1 和R 2 的含义如规范中所定义。式(I)的化合物是腺苷A 2A 受体拮抗剂，因此可用于治疗由腺苷A 2A 受体活性介导的疾病和病症。这些疾病包括但不限于中枢神经系统疾病，如抑郁症、认知功能疾病和神经退行性疾病，如帕金森病、老年性痴呆症、精神病和中风。本发明的化合物还可用于治疗注意力相关障碍，如注意力缺陷障碍（ADD）和注意力缺陷多动障碍（ADHD），额外锥体综合征，例如肌张力障碍、不安坐立、假性帕金森症和迟发性运动障碍，以及异常运动障碍，如不宁腿综合征（RLS）和睡眠中期肢体运动（PLMS）；肝硬化、纤维化和脂肪肝；在硬皮病等疾病中的皮肤纤维化；以及对成瘾行为的缓解。特别是，本发明的化合物可用于改善由帕金森病等神经退行性疾病引起的运动障碍。
• Platinum(<scp>ii</scp>) photo-catalysis for highly selective difluoroalkylation reactions
  作者：Jian-Ji Zhong、Chen Yang、Xiao-Yong Chang、Chao Zou、Wei Lu、Chi-Ming Che

  DOI：10.1039/c7cc03823b

  日期：——

  difluoroalkylation of cinnamic acids and alkynes for selective construction of E-,Z-difluoroalkyl alkenes and difluoroalkyl alkenyl iodides, respectively, were achieved under mild conditions. The high efficiency, good substrate scope and high selectivity altogether highlight the prospect of Pt(II) photocatalysts in visible-light-driven organic transformation reactions.

  在温和条件下分别实现了肉桂酸的铂（II）光催化的肉桂酸和炔烃的二氟烷基化，以选择性地构建E-，Z-二氟烷基烯烃和二氟烷基烯基碘。Pt（II）光催化剂的高效率，良好的底物范围和高的选择性，共同突出了可见光驱动的有机转化反应的前景。
• Use of Mc4 Receptor Agonist Compounds
  申请人：McMurray Gordon

  公开号：US20080234280A1

  公开（公告）日：2008-09-25

  This invention relates to the use of an MC4 receptor agonist compound for the manufacture of a medicament for the treatment of lower urinary tract dysfunction.

  该发明涉及使用MC4受体激动剂化合物制造治疗下尿路功能障碍的药物。
• Cinnamide derivatives as KCNQ potassium channel modulators
  申请人：——

  公开号：US20030166650A1

  公开（公告）日：2003-09-04

  There is provided novel cinnamide derivatives of Formula I 1 wherein R is C 1-4 alkyl or trifluoromethyl; R 1 is selected from the group consisting of pyridinyl, quinolinyl, thienyl, furanyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, chromanyl, indanyl, biphenylyl, phenyl and substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected-from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; R 2 and R 3 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, and halogen; R 4 is selected from the group consisting of di(C 1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said substituent is independently selected from the group consisting of C 1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; R 5 is hydrogen, chloro or fluoro; or R 4 and R 5 taken together are —CH═CH—CH═CH— or —X(CH 2 ) m Y— in which X and Y are each independently selected from the group consisting of CH 2 , (CH 2 ) n N(R 9 )— and O, wherein m is 1 or 2; n is 0 or 1; and R 6 , R 7 , and R 8 are each independently selected from hydrogen, chloro and fluoro; and R 9 is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxyethyl, C 1-4 alkoxyethyl, cyclopropylmethyl, —CO 2 (C 1-4 alkyl), and —CH 2 CH 2 NR 10 R 11 in which R 10 and R 11 are each independently hydrogen or C 1-4 alkyl, which are openers of the KCNQ potassium channels and are useful in the treatment of disorders which are responsive to the opening of the KCNQ potassium channels.

  提供了一种新型的苯甲酰胺衍生物，其化学式为I1，其中R为C1-4烷基或三氟甲基；R1选自吡啶基，喹啉基，噻吩基，呋喃基，1,4-苯并二氧杂环基，1,3-苯并二氧杂环基，色环基，茚基，联苯基，苯基和取代苯基，其中所述取代苯基被一个或两个取代基取代，每个取代基独立地选自卤素，C1-4烷基，C1-4烷氧基，三氟甲基，三氟甲氧基和硝基；R2和R3各自选自氢，C1-4烷基和卤素；R4选自二(C1-4烷基)氨基，三氟甲氧基和可选取代的吗啉-4-基，吡啶基，嘧啶基，哌嗪基和吡嗪基，其中所述取代基独立地选自C1-4烷基，氨甲基，羟甲基，氯或氟；R5为氢，氯或氟；或R4和R5共同为—CH═CH—CH═CH—或—X(CH2)mY—，其中X和Y各自独立地选自CH2，(CH2)nN(R9)—和O，其中m为1或2；n为0或1；R6、R7和R8各自选自氢，氯和氟；R9选自氢，C1-4烷基，羟乙基，C1-4烷氧乙基，环丙基甲基，—CO2(C1-4烷基)和—CH2CH2NR10R11，其中R10和R11各自独立地选自氢或C1-4烷基，这些化合物是KCNQ钾通道的开放剂，可用于治疗对KCNQ钾通道开放有反应的疾病。
• Pharmaceutically active compounds
  申请人：Calabrese Antony Andrew

  公开号：US20050176772A1

  公开（公告）日：2005-08-11

  The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

  本发明涉及一类通式(I)的黑色素细胞激素MCR4激动剂，其中R1、R2、R3、R4和R5如本文所定义，特别是选择性MCR4激动剂化合物，其在医学上的使用，包含它们的组成物，制备它们的过程以及用于这种过程的中间体。